GPCR — Structure Therapeutics Share News
0.000.00%
Last trade - 00:00NASDAQ RESUMED AT 09:45 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM
NASDAQ RESUMED AT 09:38 AM
U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Structure Therapeutics up after weight-loss drug succeeds mid-stage trial
Brief: Structure Therapeutics Reports Positive Topline Data From ACCESS Program For Its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Structure's pill shows up to 11% weight loss in mid-stage study (updated)
Structure's experimental pill shows 11% weight loss in study, shares up
Structure Therapeutics down ahead of weight-loss drug data
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Structure Therapeutics Q3 loss widens to $65.7 mln
Brief: Structure Therapeutics Inc. Q3 Net Income USD -65.712 Million
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Metsera the US obesity biotech at centre of Novo, Pfizer bidding war
Metsera jumps as Novo challenges Pfizer in bidding war for obesity drug developer
Factbox: Top pharma companies work to launch first weight-loss pill